Fig. 7: The 12/15-LOX/12-HETE signaling pathway controls gene expression of the complement pathway.

a Experimental setup. b, c Quantification of cd11b and c3ar mRNA expression in freshly sorted n-3 deficient and n-3 sufficient microglia, treated with baicalein or its vehicle. Means ± SEM; n = 4–6 per group. Two-way ANOVA: cd11b: diet effect, F(1,15) = 0.57, p = 0.46; treatment effect, F(1,15) = 1.37, p = 0.26; interaction, F(1,15) = 2.48, p = 0.14; c3ar: diet effect, F(1,18) = 1.36, p = 0.26; treatment effect, F(1,18) = 1.52, p = 0.23; interaction, F(1,18) = 4.36, *p = 0.051. d Experimental setup. e, f Quantification of cd11b and c3ar mRNA expression in freshly sorted n-3 deficient and n-3 sufficient microglia, exposed to synaptosomes for 2 h and treated with baicalein or its vehicle. Means ± SEM; n = 8 per group. Two-way ANOVA followed by Bonferroni post hoc test: cd11b: diet effect, F(1,28) = 0.16, p = 0.19; treatment effect, F(1,28) = 0.92, **p = 0.0028; interaction, F(1,28) = 0.072, p = 0.36; n-3 deficient + vehicle vs n-3 deficient+ baicalein, *p = 0.014; n-3 deficient + vehicle vs n-3 deficient+ baicalein, *p = 0.029; c3ar: diet effect, F(1,28) = 0.35, **p = 0.0034; treatment effect, F(1,28) = 0.0043, p = 0.72; interaction, F(1,28) = 0.0019, p = 0.81. Source data are provided as a Source data file.